Type 2 diabetes, cardiovascular risk, and the link to insulin resistance (Q35557355)

8 August 2017

1 reference

title

Type 2 diabetes, cardiovascular risk, and the link to insulin resistance (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

20 March 2024

Mark W. Stolar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14553864

20 March 2024

Robert J. Chilton

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14553864

20 March 2024

language of work or name

1 reference

1 January 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0149291803802400?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

https://api.elsevier.com/content/article/PII:S0149291803802400?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

20 March 2024

published in

Clinical Therapeutics

1 reference

8 August 2017

volume

25 Suppl B

1 reference

8 August 2017

page(s)

B4-31

1 reference

Emerging epidemic of type 2 diabetes in youth

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Prevalence of impaired glucose tolerance among children and adolescents with marked obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Insulin resistance: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Insudative lesions--their pathogenesis and association with glomerular obsolescence in diabetes: a dynamic hypothesis based on single views of advancing human diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Atherosclerosis: risk factors and the vascular endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Endothelial dysfunction in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Endothelial dysfunction in diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Endothelin: emerging role in diabetic vascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

New insights into plaque stabilisation by lipid lowering.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Atherosclerosis and diabetes: the RAGE connection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Current concepts of the pathogenesis of the acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Molecular bases of the acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Atherosclerosis: what is it and why does it occur?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Diabetes mellitus: a hypercoagulable state

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pathophysiology of insulin resistance in human disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Atherosclerosis and arterial influx of lipoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Hyperinsulinaemia in hypertensive subjects: validity of a test for the detection of insulin resistance in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Coronary artery constriction caused by the cold pressor test in human hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effect of African-American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Dyslipidaemia and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Fatty acids, hyperinsulinemia, and insulin resistance: which comes first?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

An adipocentric view of signaling and intracellular trafficking

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Adipose tissue as an endocrine organ

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Differential activation of adipogenesis by multiple PPAR isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Serum leptin concentration and insulin sensitivity in men with abdominal obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Medical hazards of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Health consequences of visceral obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Hypertension and macrovascular disease--the killing fields of NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The mode of action of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effects of pioglitazone on calcium channels in vascular smooth muscle.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Inhibition of tumor necrosis factor-alpha with anti-diabetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Improved endothelial function with metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Insulin resistance and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Effects of fibrates on serum metabolic parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Treatment of hypertension in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Thiazolidinedione-induced edema

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pulmonary edema associated with rosiglitazone and troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Pulmonary edema associated with troglitazone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980240-0

7 January 2021

Diabetes in African Americans

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats

20 March 2024

series ordinal

140

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

Pharmacological effects of a thiazolidinedione derivative, pioglitazone

20 March 2024

series ordinal

170

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80240-0

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference